RECRUITING

Studying the Neuronal Basis of Human Social Cognition

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This proposal aims to study the role that the dorsal prefrontal cortex plays in human social cognition.

Official Title

An Integrated Single-neuronal, Population-, Local Network- and Stimulation-based Prefrontal Investigation of Human Social Cognition

Quick Facts

Study Start:2022-05-20

Study Completion:2026-06-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05324579

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. 18 years old or older 2. patients able to give informed consent	1. Children under 18 2. Significant co-morbidities 3. Claustrophobia or general anxiety that may impact intraoperative testing 4. Use of CNS-active medications including stimulants and antipsychotics which may alter 5. Pregnancy 6. Operative events that will require expedition of the surgery. 7. Poor tolerance of testing by the patient 8. Increased abnormal cortical excitability 9. Necessity to administer drugs that will interfere with mapping

Inclusion Criteria

Exclusion Criteria

1. 18 years old or older
2. patients able to give informed consent

1. Children under 18
2. Significant co-morbidities
3. Claustrophobia or general anxiety that may impact intraoperative testing
4. Use of CNS-active medications including stimulants and antipsychotics which may alter
5. Pregnancy
6. Operative events that will require expedition of the surgery.
7. Poor tolerance of testing by the patient
8. Increased abnormal cortical excitability
9. Necessity to administer drugs that will interfere with mapping

Contacts and Locations

Study Contact

Ziv Williams, MD

CONTACT

6173126534

zwilliams@mgh.harvard.edu

Yoav Kfir, PhD

CONTACT

ykfir@mgh.harvard.edu

Principal Investigator

Ziv Williams, MD

PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Study Locations (Sites)

Massachusetts General Hospital

Boston, Massachusetts, 02114

United States

Rhode Island Hospital

Providence, Rhode Island, 02903

United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

Ziv Williams, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-20

Study Completion Date2026-06-01

Study Record Updates

Study Start Date2022-05-20

Study Completion Date2026-06-01

Terms related to this study

Additional Relevant MeSH Terms

Neurosciences